ArticleBioactive materials2024
Enzyme-like biomimetic oral-agent enabling modulating gut microbiota and restoring redox homeostasis to treat inflammatory bowel disease.
Article in Bioactive materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Antioxidant Activity and Metabolomic Characterization ofMicroorganisms · 2026Article
- Advances in single-cell surface engineering: nano-coating and core-shell strategies for probiotics delivery in inflammatory bowel disease.Archives of microbiology · 2026Review
- Targeted intestinal barrier repairActa pharmaceutica Sinica. B · 2026Article
- An orally administrable hydrogen-bonded organic framework (HOF)-based nanoreactor to reprogram metabolism for senescence intervention.National science review · 2026Article
- Microbial profiling of five traditional Chinese medicines: culture-based identification vs. 16S rRNA sequencing.Journal of medical microbiology · 2026Article
- Construction of a nanozyme composite drug delivery system based on columbianadin for inflammatory bowel disease therapy.RSC advances · 2026Article
- Real-time near-infrared II fluorescence navigation of magnetic nanorobots for image-guided therapy.Science advances · 2026Article
- Nanozymes in Therapeutic Prospects and Challenges for Autoimmune Diseases.International journal of nanomedicine · 2026Review
- Preparation of hierarchically targetable Astragalus polysaccharide lipid nanoparticles and study on their therapeutic effect on orthotopic colon cancer.Materials today. Bio · 2025Article
- NIR-controlled photothermal intelligent nanozyme synergizes catalysis and gas therapy for multidimensional treatment of inflammatory bowel disease.Journal of nanobiotechnology · 2025Article
- Biallelic BRF2 mutations disrupt redox homeostasis as etiological factors in syndromic immunodeficiency and developmental disorders.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Pathogenesis guided application of nanozymes in the treatment of inflammatory bowel disease.Materials today. Bio · 2025Review
- Colonic Submucosa Targeted Delivery of Probiotic and Rhein for Ulcerative Colitis Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Research trends and hotspots of nanomaterials in inflammatory bowel disease: a bibliometric analysis.Nanomedicine (London, England) · 2025Review
- ZnO@Cu5.4O Nanoparticle Alleviates Inflammatory Responses of Intestinal Epithelial Cells by Inhibiting the Expression of GSDMB.ACS omega · 2025Article
- A cerium nanocluster for effective alleviation of inflammatory bowel disease by scavenging RONS and regulating gut microbiome.Materials today. Bio · 2025Article
- Longitudinal multi-omics analysis of the gut-liver axis: Unraveling the molecular mechanisms of metabolic homeostasis regulation by Pd@Pt nanozymes.Materials today. Bio · 2025Article
- A Nanosystem Alleviates Severe Acute Pancreatitis via Reactive Oxygen Species Scavenging and Enhancing Mitochondrial Autophagy.Nano letters · 2025Article
- Orally Administered Functional Polyphenol-Nanozyme-Armored Probiotics for Enhanced Amelioration of Intestinal Inflammation and Microbiota Dysbiosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Copper-luteolin nanocomplexes for Mediating multifaceted regulation of oxidative stress, intestinal barrier, and gut microbiota in inflammatory bowel disease.Bioactive materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactive oxygen species (ROS), immune dysregulation-induced inflammatory outbreaks and microbial imbalance play critical roles in the development of inflammatory bowel disease (IBD). Herein, a novel enzyme-like biomimetic oral-agent ZnPBA@YCW has been developed, using yeast cell wall (YCW) as the outer shell and zinc-doped Prussian blue analogue (ZnPBA) nanozyme inside. When orally administered, the ZnPBA@YCW is able to adhere to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.